I

Invivyd

Develops monoclonal antibodies for viral protection

Senior Vice President - Technical Operations

Full-TimeUpdated on 10/15/2026
$304k - $425k
Expert
PhD
New Haven, CT, USA
HybridAt least three in-office days per week (Monday, Tuesday, and Wednesday).
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • A PhD or equivalent in Biochemical Engineering, Biochemistry, or an equivalent field, with biologics experience including antibody-based development and manufacturing.
  • At least 15 years of experience in the pharmaceutical and/or biotechnology industry.
  • Multiple years of management experience leading a collaborative team.
  • A proven record of overseeing a department, including staffing and budget activities.
  • Experience with biologics development, including process, analytical, and formulation development activities.
  • Experience with early- and late-clinical-stage CMC development, including validation and commercialization.
  • Experience with CDMOs, including selection and management; knowledge of cGMPs is essential.
  • CMC regulatory experience, including IND/IMPD filings and BLA submissions.
  • Excellent leadership and interpersonal skills, with the ability to engender credibility and confidence within and outside the company.
  • A science- and data-driven approach.
Responsibilities
  • Provide leadership and direction for the Technical Operations group, with responsibility for strategy, direction, and execution of technical initiatives in partnership across the organization.
  • Oversee the Technical Operations group, including CMC Development, Manufacturing (drug substance and drug product), Supply Chain and Distribution, and Quality Control.
  • Develop and execute the overall clinical and commercial manufacturing strategy, including planning, contracting, CDMO oversight, execution, supply, and distribution.
  • Direct CMC development activities, including process, analytical, and formulation activities for clinical and commercial product candidates.
  • Provide technical operations oversight for strategic decision-making.
  • Lead interactions with CDMOs and other contract services needed to execute the Technical Operations plan and strategy.
  • Support other functional areas in developing and communicating the overall corporate strategy.
  • Coordinate with Regulatory Affairs to develop and communicate CMC regulatory strategies aligned with the company’s objectives.
  • Represent the company to external audiences, including regulatory authorities and biotechnology industry collaborators and partners.
  • Build working relationships across departments to promote transparency and facilitate communication.
  • Lead the team through planning for cross-functional transitions.
Desired Qualifications
  • Start-up experience is strongly preferred.
  • Experience in a development organization, including integration with research, non-clinical, and clinical groups.

About the company

Invivyd develops antibody-based therapies to protect immunocompromised people from viral threats. It discovers and optimizes monoclonal antibodies using viral surveillance, predictive modeling, and antibody engineering, aiming to prevent infections such as COVID-19 in high-risk groups. Its lead candidate VYD222 targets prevention of symptomatic COVID-19 in transplant recipients and people with blood cancers. The company plans to commercialize these antibodies through development, approvals, and partnerships, while pursuing government funding to support research for vulnerable populations.

Company Size

51-200

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2020

Get referred to Invivyd

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • PEMGARDA revenue grew 22% year over year in Q1 2026.
  • Invivyd completed LIBERTY enrollment June 16, 2026, accelerating VYD2311 decision-making.
  • Marc Elia became CEO on September 1, 2026, signaling urgency after trial progress.

What critics are saying

  • Invivyd disclosed substantial doubt about continuing as a going concern in August 2026.
  • PEMGARDA's EUA terminates June 29, 2027, threatening Invivyd's main revenue engine.
  • VYD2311 still faces Phase 3, FDA, and commercialization uncertainty after Q3 2026 data.

What makes Invivyd unique

  • Invivyd pairs surveillance-driven antibody design with rapid COVID variant updating.
  • PEMGARDA serves immunocompromised patients needing vaccine alternatives, a niche big pharmas ignore.
  • VYD2311 targets intramuscular prophylaxis, potentially improving access versus infusion-only antibodies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Professional Development Budget
  • Flexible Work Hours

Company News

Yahoo Finance
May 18th, 2026
Invivyd reports $13.7M Q1 revenue, 22% growth, advances COVID-19 monoclonal antibody trial

Invivyd Inc. reported first-quarter earnings on 14 May, with PEMGARDA net product revenue reaching $13.7 million, up 22% year-on-year. The biopharmaceutical company ended the quarter with $184.2 million in cash, supplemented by approximately $20 million from an at-the-market offering in April. The company posted a net loss of $41.4 million, driven by increased operating expenses related to its DECLARATION Phase 3 clinical trial for VYD2311, a COVID-19 monoclonal antibody candidate. The trial achieved initial full enrollment in March, with top-line data now expected in the third quarter. Invivyd is preparing additional Phase 3 trials and advancing its pipeline beyond COVID-19, including VMS063 for measles and VBY329 for paediatric respiratory syncytial virus prophylaxis.

Yahoo Finance
May 14th, 2026
Invivyd reports 22% YoY PEMGARDA revenue growth amid clinical trial investments

Invivyd Inc reported strong revenue growth in its Q1 2026 earnings call, with monoclonal antibody revenues continuing to grow and PEMGARDA revenue increasing 22% year-over-year compared to Q1 2025. The company accelerated recruitment for its pivotal DECLARATION trial, exceeding internal expectations, though recruitment slowed during a lull in COVID-19 cases. The company confirmed virus neutralisation against the Omicron BA.3.2 variant and is expanding its early discovery pipeline to include antibodies for measles, mumps, rubella and Lyme disease. Invivyd reported significant clinical spending on the DECLARATION trial but expects R&D spending to normalise as the VYD2311 trial concludes. The company strengthened its cash position through additional funding raised in April and received positive feedback from policymakers on increased government affairs activity.

Yahoo Finance
Mar 5th, 2026
Invivyd eyes mid-2026 data for COVID antibody VYD2311 as PEMGARDA revenue jumps 31%

Invivyd reported Q4 2025 earnings, highlighting strategic progress in monoclonal antibody prophylaxis as an alternative to COVID-19 vaccine boosting. The company's Declaration study for VYD2311 reached target enrolment of approximately 1,770 subjects, with mid-year 2026 remaining the target for pivotal data. PEMGARDA revenue grew 31% sequentially, supporting infrastructure development ahead of a potential VYD2311 launch. Management expects to decide on expanding the trial by roughly 30% in April to ensure statistical power if community attack rates fluctuate. The company reported cash of $226.7 million, providing runway through the mid-2026 data readout. Invivyd is expanding into long COVID and post-vaccine syndrome, whilst developing RSV and measles programmes with a paediatric-first approach. Management cited COVID-19 community attack rates as the primary external risk factor.

Yahoo Finance
Mar 5th, 2026
Invivyd appoints Harvard epidemiologist Michael Mina as chief medical officer

Invivyd has appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer. Dr Mina is a former assistant professor of epidemiology, immunology and infectious disease at Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital. Dr Mina gained prominence during the COVID pandemic, advising governments on testing policies and leading the US government's Home Test-to-Treat Programme. His research includes discovering measles-induced "immune amnesia" and investigating antibody responses to vaccines and pathogens. He has published over 100 scientific papers with more than 10,000 citations. The appointment comes as Invivyd works to expand its pipeline of monoclonal antibodies for infectious disease prevention, including COVID, RSV and measles.

Yahoo Finance
Mar 5th, 2026
Invivyd reports $17.2M Q4 revenue for PEMGARDA, raises $200M to fund VYD2311 COVID trial

Invivyd reported fourth quarter 2025 net product revenue of $17.2 million for PEMGARDA (pemivibart), representing 25% year-over-year growth and 31% quarter-over-quarter growth. Full-year revenue more than doubled whilst operating expenses were reduced by nearly half. The company ended 2025 with $226.7 million in cash after raising over $200 million in financing transactions during the second half of the year. Invivyd has initiated the DECLARATION Phase 3 pivotal trial of VYD2311, a vaccine-alternative antibody to prevent COVID, with top-line data expected mid-2026. The FDA granted Fast Track designation for VYD2311 in December 2025. The trial has achieved full enrolment and an independent data monitoring committee has recommended allowing pregnant and breastfeeding women to participate. A potential trial re-sizing decision could occur in April.